Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and tolerability of bendamustine
as combination therapy with bortezomib for patients with relapsed/refractory multiple myeloma
(MM).